Nikos P, Ayoola OA, Aris R. Dyslipidemia [Internet]. NLM NCBI. [Accessed 23 July 2024]. https://www.ncbi.nlm.nih.gov/books/NBK560891/

Vikrama R, Carlos A, Nasreen A, Yogeyaa SC, Hussein E, Marat E et al. non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis.2023;383(117312):1–10. https://doi.org/10.1016/j.atherosclerosis.2023.117312

Angela P, Manuela C, Elena O, Giuseppe DN, Alberico LC. Global epidemiology of dyslipidemias. Nat Rev Cardiol. 2021;18(10):689–700. https://doi.org/10.1038/s41569-021-00541-4.

Article  CAS  Google Scholar 

Nuntakorn T, Renan S, Elmer JBL, Zhen-Vin L. Dyslipidemia management for primary prevention of cardiovascular events. Elsevier PMR. 2022;27(101819):1–13. https://doi.org/10.1016/j.pmedr.2022.101819.

Article  Google Scholar 

Report of WHO Scientific Group. Cardiovascular disease risk factors: New areas for research WHO Technical Report Series No 841. 1994 Geneva WHO.

Mosca S, Araújo G, Costa V, Correia J, Bandeira A, Martins E, Mansilha H, Tavares M, Coelho MP. Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents. J Nutr Metab. 2022;2022:4782344. https://doi.org/10.1155/2022/4782344. PMID: 35237450; PMCID: PMC8885266.

Ferranti SD, Newburger JW. Dyslipidemia in children: management. Waltham, MA, USA: UpToDate; 2020. [Google Scholar].

Google Scholar 

Hoff Mann GF, Zschocke J, Nyhan WL. Inherited metabolic Diseases-A Clinical Approach. Berlin, Germany: Springer; 2017. [Google Scholar].

Book  Google Scholar 

Rae-Ellen W, Kavey. Combined Dyslipidemia in Children and Adolescents. Endotext [Internet]. [Accessed 23 July 2024]. https://www.ncbi.nlm.nih.gov/books/NBK395577

Michael HD, Pallavi P. Dyslipidemia [Internet]. MSD MANUAL. [Accessed 23 July 2024]. https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia

Mohammed SO, Getu A, Nefsu A, Bedru J, Tamiru T, Nugusu A, et al. Determinants of Dyslipidemia in Africa: a systematic review and Meta-analysis. Front Cardiovasc Med. 2022;8(778891):1–13. https://doi.org/10.3389/fcvm.2021.778891.

Article  Google Scholar 

Bedasa A, Shiferaw B, Temesgen BW, Agete TH, Waqota C. Dyslipidemia and its associated factors among adult cardiac patients at Ambo university referral hospital, Oroma region, west Ethiopia. BMC Cardiovasc Disord. 2023;23(321). https://doi.org/10.1186/s12872-023-03348-y.

Dave JA, Levitt NS, Ross IL, Lacerda M, Maartens G, Blom D. Anti-retroviral therapy increases the prevalence of dyslipidemia in South African HIV-infected patients. PLoS ONE. 2016;11:e0151911. https://doi.org/10.1371/journal.pone.0151911.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia Pu, Robert R, Beinan Z, Kristen MJA, Katherine GH, Vani N, et al. Dyslipidemia in Special ethnic populations. Cardiol Clin. 2016;33(2):325–33. https://doi.org/10.1016/2Fj.ccl.2015.01.005

Google Scholar 

Manjari R, Anis R. Familial Hyperchylomicronemia Syndrome [Internet]. [Accessed 23 July 2024]. https://www.ncbi.nlm.nih.gov/books/NBK551655

Falko JM. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. Endocr Pract. 2018;24(8):756–63.

Article  PubMed  Google Scholar 

Garay García KJ, Chong Menendez RJ, Nogueira JP, Piedra Andrade JS. Familial chylomicronemia syndrome: The first case reported in Ecuador. Clin Investig Arterioscler. 2022;34(6):326–9. English, Spanish. https://doi.org/10.1016/j.arteri.2022.08.002. Epub 2022 Sep 30. PMID: 36184299.

Ronald BG, Alan CA, Comprehensive Update on the Chylomicronemia Syndrome. Front Endocrinol (Lausanne). 2020;11:593931. https://doi.org/10.3389/2Ffendo.2020.593931.

Article  Google Scholar 

Lena R, Dominik S, Krzysztof L, Andrzej L, Agniezka G. Familial partial Lipodystrophy_ Literature Review and Report of a Novel variant in PPARG expanding the spectrum of Disease-causing alterations in FPLD3. Diagnostics (Basel). 2022;12(5):1122. https://doi.org/10.3390/2Fdiagnostics12051122.PMID:35626178.

Article  Google Scholar 

Vincent P, Aparna S, Robert D, Oluseye O, Jihwan P, Vasanth S, Seth SM. Abstract 14986: Modern Prevalence of Familial Chylomicronemia Syndrome [Online}. 2019;40(1). [Accessed 23 July 2024]. https://www.ahajournalshttps://doi.org/10.1161/circ.140.suppl/1.14986

Dirk JB, Louis O’Dea, Andres D, Veronica JA, Ewa KP, Karren RW, et al. Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study. J Clin Lipidol. 2018;12(5):1234–43. https://doi.org/10.1016/j.jacl.2018.05.013.

Article  Google Scholar 

Gaudet D, Digenio A, Alexander VJ, Investigators, obotA. The APPROACH study. A Randomized, Double-Blind, Placebo-Controlled, phase 3 study of Volanesorsen Administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). J Clin Lipidol. 2017;11:814–5. https://doi.org/10.1016/j.jacl.2017.04.071.

Richard AF, Thorsten L, Seth SM, Maclej B, Steven RJ, Peter PT. Contemporary management of Dyslipidemia. Springer Nat Drugs. 2022;82:559–76. https://doi.org/10.1007/s40265-022-01691-6.

Article  CAS  Google Scholar 

Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexander VJ, Xia S, Hurh E, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019;40:2785–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patrick C. FDA Grants Priority Review for Olezarsen in Familial Chylomicronemia Syndrome [Internet]. HCP Live. [Accessed 23 July 2024]. https://www.hcplive.com/view/fda-grants-priority-review-for-olezarsen-in-familial-chylomicronemia-syndrome

FDA grants orphan drug status to Ionis. ’olezarsen for FCS treatment [Internet]. Pharmaceutical Today. [Accessed 23 July 2024]. https://www.pharmaceutical-technology.com/news/fda-ionis-olezarsen-fcs/

Pipeline [Internet]. Arrowhead pharmaceuticals. [Accessed 23 July 2024]. Available from: https://arrowheadpharma.

Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, Soran H, Prohaska TA, Xia S, Ginsberg HN, Witztum JL, Tsimikas S. Balance investigators. Olezarsen, Acute Pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781–92. https://doi.org/10.1056/NEJMoa2400201. Epub 2024 Apr 7. PMID: 38587247.

Article  CAS  PubMed  Google Scholar 

Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Murphy SA, Goodrich EL, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS. Bridge–TIMI 73a investigators. Olezarsen for Hypertriglyceridemia in patients at High Cardiovascular Risk. N Engl J Med. 2024;390(19):1770–80. https://doi.org/10.1056/NEJMoa2402309. Epub 2024 Apr 7. PMID: 38587249.

Article  CAS  PubMed  Google Scholar 

Jean-Claude Ewa KP, Eric SA, Christine MB, Michael DS, Patrick MM. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401–12. https://doi.org/10.1093/eurheartj/ehab820.

Article  CAS  Google Scholar 

Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, San Martin J, Hellawell J, Ballantyne CM. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024;9(7):620–30. https://doi.org/10.1001/jamacardio.2024.0959. PMID: 38583092; PMCID: PMC11000138.

Article  PubMed  Google Scholar 

Pappan N, Awosika AO, Rehman A, Dyslipidemia. NCBI Bookshelf [Internet]. 2024;1–15. https://www.ncbi.nlm.nih.gov/books/NBK560891/

Chebli J, Larouche M, Gaudet D. APOC3 siRNA and ASO therapy for dyslipidemia. Curr Opin Endocrinol Diabetes Obes. 2024;31(2):70–7.

Article  CAS  PubMed  Google Scholar 

Spagnuolo Catherine MRAH. Etiology and emerging treatments for familial chylomicronemia syndrome. Expert Rev Endocrinol Metab [Internet]. 2024;19(4):299–306. https://doi.org/10.1080/17446651.2024.2365787

Srikanth S, Deedwania P. Management of Dyslipidemia in patients with hypertension, diabetes, and metabolic syndrome. Curr Hypertens Rep. 2016;18(10):11906.

Article  Google Scholar 

Erik Swain. Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome. Cardiologytoday [Internet]. 2024; https://www.healio.com/news/cardiology/20240606/olezarsen-safely-lowers-triglycerides-in-patients-with-familial-chylomicronemia-syndrome

Lou N, Plozasiran Paves RNA. Interference Path to Triglyceride Reduction. MedPage Today [Internet]. 2024; https://www.medpagetoday.com/cardiology/dyslipidemia/110354

Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D. Plozasiran, an RNA interference Agent Targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):899–912. https://doi.org/10.1056/NEJMoa2404143. Epub 2024 May 28. PMID: 38804517.

Article  CAS  PubMed  Google Scholar 

Kayani T, Ahmad B, Chang RS, Qian F, Sahinoz M, Rehan MW, Giaimo A, Spatz ES, Hu JR. Beyond statins: novel lipid-lowering agents for reducing risk of atherosclerotic Cardiovascular Disease. Pharmacoepidemiology. 2024;3:117–68. https://doi.org/10.3390/pharma3010009.

Article  Google Scholar 

Kim K, Ginsberg HN, Choi SH, New. Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes Metab J. 2022;46(4):517–532. doi: 10.4093/dmj.2022.0198. Epub 2022 Jul 27. Erratum in: Diabetes Metab J. 2022;46(5):817–818. https://doi.org/10.4093/dmj.2022.0295. PMID: 35929170; PMCID: PMC9353557.

Gragnano F, Natale F, Concilio C, Fimiani F, Cesaro A, Sperlongano S, Crisci M, Limongelli G, Calabrò R, Russo M, Golia E, Calabrò P. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. J Cardiovasc Med (Hagerstown). 2018;19(2):75–77. https://doi.org/10.2459/JCM.0000000000000611. PMID: 29251697.

Klobučar MS, Cvijanović PO, Detel D, Kenđel JG, Bakula M, Rahelic D. Dyslipidemia: Current Perspectives and Implications for Clinical Practice. Manag Dyslipidemia. 2021.

Gaudet D, Gipe DA, Porda J. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces triglycerides in humans. N Engl J Med. 2020;383(7):617–27.

Google Scholar 

Crooke ST, Witztum JL, Bennett CF, et al. Antisense oligonucleotides for the treatment of rare genetic diseases. J Clin Invest. 2020;130(1):3–12.

Google Scholar 

BRIDGE-TIMI 73a. Novel olezarsen reduces triglycerides, ApoC3, ApoB levels.https://www.acc.org/Latest-in Cardiology/Articles/2024/04/02/17/02/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2024%2f04%2f02%2f17%2f02%2fsun-8am-bridge-timi-acc-2024. Accessed Aug 31, 2024.